Cardiometabolic Disorders News

Metabolite profiles demonstrate that eating a healthy plant-based diet rich in whole grains, fruits, vegetables and nuts can lower one’s risk for developing type 2 diabetes, according to study findings published in Diabetologia.

WASHINGTON — Finerenone was beneficial in primary and secondary prevention across the spectrum of patients with chronic kidney disease and type 2 diabetes regardless of whether they had atherosclerotic CVD, researchers reported.

During the past 2 decades, Endocrine Today has reported on the latest developments in hormone therapy for symptoms associated with menopause. For its 20th year, the publication is taking a look back.

WASHINGTON — Patients with acute HF assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo, with benefit seen as early as 15 days, data show.

New findings published in Diabetic Medicine highlighted the urgent need for clear, evidence-based guidelines for managing nonalcoholic fatty liver disease in individuals with type 2 diabetes.

WASHINGTON — The dual SGLT inhibitor sotagliflozin reduced total CV death, MI and stroke in adults with type 2 diabetes and chronic kidney disease both with and without prior CVD, according to new analyses of the SCORED trial.

WASHINGTON — Treatment with vupanorsen, a novel antisense oligonucleotide targeting hepatic ANGPTL3, achieved modest reductions in non-HDL at 24 weeks at all doses studied, according to results of the TRANSLATE-TIMI 70 trial.

Children of mothers who used cannabis during pregnancy had greater fat mass and adiposity and higher fasting glucose than those not exposed to cannabis, according to study findings.

Healthy nonobese adults consumed more calories, gained more weight and experienced an increase in visceral adipose tissue after 14 days of experimental sleep restriction compared with those who slept 9 hours per night, researchers reported.

Both 15 mg and 30 mg pioglitazone doses have similar efficacy as 45 mg for preventing new-onset diabetes, stroke and myocardial infarction but with lower risk for adverse events, according to study findings.